Is 18 F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons.

MLA

Karlsen, William, et al. “Is 18 F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons.” Cancers, vol. 16, no. 11, June 2024, p. 1990. EBSCOhost, https://doi.org/10.3390/cancers16111990.

APA

Karlsen, W., Akily, L., Mierzejewska, M., Teodorczyk, J., Bandura, A., Zaucha, R., & Cytawa, W. (2024). Is 18 F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons. Cancers, 16(11), 1990. https://doi.org/10.3390/cancers16111990

Chicago

Karlsen, William, Lin Akily, Monika Mierzejewska, Jacek Teodorczyk, Artur Bandura, Renata Zaucha, and Wojciech Cytawa. 2024. “Is 18 F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons.” Cancers 16 (11): 1990. doi:10.3390/cancers16111990.